Jump to ratings and reviews
Rate this book

FDA Regulatory Affairs

Rate this book
Examines harmonization of the US Federal Food, Drug, and Cosmetic Act with international regulations as they apply to human drug and device development, research, manufacturing, and marketing. The Second Edition focuses on the new drug approval process, cGMPs, GCPs, quality system compliance, and corresponding documentation requirements. Written in a jargon-free style, it draws information from a wide range of resources. It demystifies the inner workings of the FDA and facilitates an understanding of how it operates with respect to compliance and product approval.

FDA Regulatory Affairs :

provides a blueprint to the FDA and drug, biologic, and medical device development offers current, real-time information in a simple and concise format contains a chapter highlighting the new drug application (NDA) process discusses FDA inspection processes and enforcement options includes contributions from experts at companies such as Millennium and Genzyme, leading CRO’s such as PAREXEL and the Biologics Consulting Group, and the FDA Three all-new chapters

clinical trial exemptions advisory committees provisions for fast track

464 pages, Hardcover

First published December 23, 2003

Loading...
Loading...

About the author

Ratings & Reviews

What do you think?
Rate this book

Friends & Following

Create a free account to discover what your friends think of this book!

Community Reviews

5 stars
12 (37%)
4 stars
14 (43%)
3 stars
5 (15%)
2 stars
1 (3%)
1 star
0 (0%)
Displaying 1 - 3 of 3 reviews
Profile Image for David Usharauli.
157 reviews3 followers
September 6, 2015
This book, edited by Douglas Pisano and David Mantus, is a compilation of FDA related regulations and law applicable to biotech/biopharma drug development.

Of course, no single book can provide full picture of FDA. Though I would say this book does some decent job, especially one chapter with tips how to find FDA related information online. Chapter about IND is also quite good.

Primary interest in this book from scientist's point of view are chapters about IND and NDA applications. For example, new law enacted in 2012 increased by 60 days both standard and priority review times necessary for NDA processing (8 months for priority review and 12 months for standard review).

Also, I learned that until FDA approves new drug, drug manufacturer or its associates cannot mention anywhere that their drug is "safe" or "effective". I did not realize that such rule existed. In my work, I frequently encounter science articles where IND/NDA-associated drug is discussed. I have not paid attention before but now it will interested to verify how strongly drug-sponsors adhere to this FDA regulation.

posted by David Usharauli

http://davidusharaulibookidealist.blo...
Profile Image for Aca.
228 reviews
January 3, 2017
Generous, straightforward and not overwhelming introduction to FDA regulations and components.
Displaying 1 - 3 of 3 reviews